eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) will host a Third Quarter 2025 update webinar on Thursday, November 13, 2025 at 5:00 PM ET.

CEO Michael Heltzen and select management will review Q3 2025 developments, ongoing initiatives, anticipated milestones, and hold a Q&A for investors. Investors can pre-register and access the live webinar via the company’s investor relations website at https://exozymes.com/investor#webinar.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 10, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Thursday, November 13, 2025 at 5:00 PM Eastern Time to discuss its results for the third quarter of 2025.

Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.

Investors can pre-register now for the webinar HERE. The live webinar can also be accessed on the day of the event through eXoZymes' investor relations website at https://exozymes.com/investor#webinar

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more on exozymes.com

eXoZymes Safe Harbor

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

When is eXoZymes (EXOZ) hosting its Q3 2025 update webinar?

The webinar is scheduled for Thursday, November 13, 2025 at 5:00 PM Eastern Time.

Who will lead the eXoZymes (EXOZ) Q3 2025 investor call?

CEO Michael Heltzen will lead the call with select members of management.

What topics will eXoZymes (EXOZ) cover in the November 13, 2025 webinar?

Management will review Q3 2025 developments, ongoing initiatives, anticipated milestones, and host a Q&A.

How can investors register for the eXoZymes (EXOZ) November 13 webinar?

Investors can pre-register or access the live webinar via https://exozymes.com/investor#webinar.

Will there be a question-and-answer session on the eXoZymes (EXOZ) Q3 2025 webinar?

Yes. The company said management will host a Q&A session during the webinar.

Can I access a replay of the eXoZymes (EXOZ) Q3 2025 webinar after November 13, 2025?

The announcement directs investors to the investor relations site; any replay availability will be posted at https://exozymes.com/investor#webinar.